ParkinsonCanadaV1, PascalFrancis, Corpus, bibRecord, 000626

Diagnosis and management of Parkinson's disease dementia

Identifieur interne : 000626 ( PascalFrancis/Corpus ); précédent : 000625; suivant : 000627

Diagnosis and management of Parkinson's disease dementia

Auteurs : W. Poewe ; S. Gauthier ; D. Aarsland ; J. B. Leverenz ; P. Barone ; D. Weintraub ; E. Tolosa ; B. Dubois

Source :

International journal of clinical practice : (Esher) [ 1368-5031 ] ; 2008.

RBID : Pascal:08-0445025

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Diagnostic, Conduite à tenir, Démence, Médecine.

English descriptors

KwdEn :
- Clinical management, Dementia, Diagnosis, Medicine, Parkinson disease.

Abstract

Parkinson's disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer's disease (AD). Cholinergic deficits, a feature of both AD and PDD, underlie the rationale for cholinesterase inhibitor therapy in both conditions. In clinical practice, it is important that PDD should be recognised and appropriately treated. This review aims to outline the recently proposed clinical diagnostic criteria for PDD and to summarise the guidelines/recommendations published since 2006 on the use of cholinesterase inhibitors in the management of PDD. Although the cholinesterase inhibitor rivastigmine has recently been approved for the management of PDD, there remains a need for the development of novel therapies that can affect key mechanisms of the disease or prevent/delay patients with PD and mild cognitive impairment from progressing to PDD.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 1368-5031`
A03		`1`		`@0 Int. j. clin. pract. : (Esher)`
A05				`@2 62`
A06				`@2 10`
A08	`01`	`1`	`ENG`	`@1 Diagnosis and management of Parkinson's disease dementia`
A11	`01`	`1`		`@1 POEWE (W.)`
A11	`02`	`1`		`@1 GAUTHIER (S.)`
A11	`03`	`1`		`@1 AARSLAND (D.)`
A11	`04`	`1`		`@1 LEVERENZ (J. B.)`
A11	`05`	`1`		`@1 BARONE (P.)`
A11	`06`	`1`		`@1 WEINTRAUB (D.)`
A11	`07`	`1`		`@1 TOLOSA (E.)`
A11	`08`	`1`		`@1 DUBOIS (B.)`
A14	`01`			`@1 Department of Neurology, Medical University Innsbruck @2 Innsbruck @3 AUT @Z 1 aut.`
A14	`02`			`@1 Alzheimer's Disease Research Unit, McGill Centre for Studies in Aging, Douglas Mental Health University Institute @2 Montréal, QC @3 CAN @Z 2 aut.`
A14	`03`			`@1 Norweigen Centre for Movement Disorders, Stavenger University Hospital @2 Stavenger @3 NOR @Z 3 aut.`
A14	`04`			`@1 Institute of Clinical Medicine, University of Bergen @2 Bergen @3 NOR @Z 3 aut.`
A14	`05`			`@1 Mental Illness and Parkinson's Disease Research Education and Clinical Centers, VA-PSHCS, and Departments of Neurology and Psychiatry and Behavioral Sciences, University of Washington @2 Seattle, WA @3 USA @Z 4 aut.`
A14	`06`			`@1 Dipartimento di Scienze Neurologiche, Università Federico II di Napoli @2 Naples @3 ITA @Z 5 aut.`
A14	`07`			`@1 Department of Psychiatry, University of Pennsylvania @2 Philadelphia, PA @3 USA @Z 6 aut.`
A14	`08`			`@1 Parkinson's Disease and Movement Disorders Unit, Institut Clinic de Neurociencies, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic de Barcelona, Institut d'lnvestigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona @2 Barcelona @3 ESP @Z 7 aut.`
A14	`09`			`@1 INSERM.UPMC UMRS 610, Federation of Neurology, Salpêtrière Hospital; University of Paris @2 Paris @3 FRA @Z 8 aut.`
A20				`@1 1581-1587`
A21				`@1 2008`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 15561 @5 354000185233900160`
A44				`@0 0000 @1 © 2008 INIST-CNRS. All rights reserved.`
A45				`@0 47 ref.`
A47	`01`	`1`		`@0 08-0445025`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 International journal of clinical practice : (Esher)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Parkinson's disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer's disease (AD). Cholinergic deficits, a feature of both AD and PDD, underlie the rationale for cholinesterase inhibitor therapy in both conditions. In clinical practice, it is important that PDD should be recognised and appropriately treated. This review aims to outline the recently proposed clinical diagnostic criteria for PDD and to summarise the guidelines/recommendations published since 2006 on the use of cholinesterase inhibitors in the management of PDD. Although the cholinesterase inhibitor rivastigmine has recently been approved for the management of PDD, there remains a need for the development of novel therapies that can affect key mechanisms of the disease or prevent/delay patients with PD and mild cognitive impairment from progressing to PDD.
C02	`01`	`X`		`@0 002B01`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Diagnostic @5 02`
C03	`02`	`X`	`ENG`	`@0 Diagnosis @5 02`
C03	`02`	`X`	`SPA`	`@0 Diagnóstico @5 02`
C03	`03`	`X`	`FRE`	`@0 Conduite à tenir @5 03`
C03	`03`	`X`	`ENG`	`@0 Clinical management @5 03`
C03	`03`	`X`	`SPA`	`@0 Actitud médica @5 03`
C03	`04`	`X`	`FRE`	`@0 Démence @5 04`
C03	`04`	`X`	`ENG`	`@0 Dementia @5 04`
C03	`04`	`X`	`SPA`	`@0 Demencia @5 04`
C03	`05`	`X`	`FRE`	`@0 Médecine @5 05`
C03	`05`	`X`	`ENG`	`@0 Medicine @5 05`
C03	`05`	`X`	`SPA`	`@0 Medicina @5 05`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 41`
C07	`05`	`X`	`ENG`	`@0 Nervous system diseases @5 41`
C07	`05`	`X`	`SPA`	`@0 Sistema nervioso patología @5 41`
N21				`@1 287`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 08-0445025 INIST
ET :	Diagnosis and management of Parkinson's disease dementia
AU :	POEWE (W.); GAUTHIER (S.); AARSLAND (D.); LEVERENZ (J. B.); BARONE (P.); WEINTRAUB (D.); TOLOSA (E.); DUBOIS (B.)
AF :	Department of Neurology, Medical University Innsbruck/Innsbruck/Autriche (1 aut.); Alzheimer's Disease Research Unit, McGill Centre for Studies in Aging, Douglas Mental Health University Institute/Montréal, QC/Canada (2 aut.); Norweigen Centre for Movement Disorders, Stavenger University Hospital/Stavenger/Norvège (3 aut.); Institute of Clinical Medicine, University of Bergen/Bergen/Norvège (3 aut.); Mental Illness and Parkinson's Disease Research Education and Clinical Centers, VA-PSHCS, and Departments of Neurology and Psychiatry and Behavioral Sciences, University of Washington/Seattle, WA/Etats-Unis (4 aut.); Dipartimento di Scienze Neurologiche, Università Federico II di Napoli/Naples/Italie (5 aut.); Department of Psychiatry, University of Pennsylvania/Philadelphia, PA/Etats-Unis (6 aut.); Parkinson's Disease and Movement Disorders Unit, Institut Clinic de Neurociencies, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic de Barcelona, Institut d'lnvestigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona/Barcelona/Espagne (7 aut.); INSERM.UPMC UMRS 610, Federation of Neurology, Salpêtrière Hospital; University of Paris/Paris/France (8 aut.)
DT :	Publication en série; Niveau analytique
SO :	International journal of clinical practice : (Esher); ISSN 1368-5031; Royaume-Uni; Da. 2008; Vol. 62; No. 10; Pp. 1581-1587; Bibl. 47 ref.
LA :	Anglais
EA :	Parkinson's disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer's disease (AD). Cholinergic deficits, a feature of both AD and PDD, underlie the rationale for cholinesterase inhibitor therapy in both conditions. In clinical practice, it is important that PDD should be recognised and appropriately treated. This review aims to outline the recently proposed clinical diagnostic criteria for PDD and to summarise the guidelines/recommendations published since 2006 on the use of cholinesterase inhibitors in the management of PDD. Although the cholinesterase inhibitor rivastigmine has recently been approved for the management of PDD, there remains a need for the development of novel therapies that can affect key mechanisms of the disease or prevent/delay patients with PD and mild cognitive impairment from progressing to PDD.
CC :	002B01; 002B17G
FD :	Maladie de Parkinson; Diagnostic; Conduite à tenir; Démence; Médecine
FG :	Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du système nerveux central; Pathologie du système nerveux
ED :	Parkinson disease; Diagnosis; Clinical management; Dementia; Medicine
EG :	Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases
SD :	Parkinson enfermedad; Diagnóstico; Actitud médica; Demencia; Medicina
LO :	INIST-15561.354000185233900160
ID :	08-0445025

Links to Exploration step

Pascal:08-0445025

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Diagnosis and management of Parkinson's disease dementia</title>
<author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">W. Poewe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gauthier, S" sort="Gauthier, S" uniqKey="Gauthier S" first="S." last="Gauthier">S. Gauthier</name>
<affiliation><inist:fA14 i1="02"><s1>Alzheimer's Disease Research Unit, McGill Centre for Studies in Aging, Douglas Mental Health University Institute</s1>
<s2>Montréal, QC</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Aarsland, D" sort="Aarsland, D" uniqKey="Aarsland D" first="D." last="Aarsland">D. Aarsland</name>
<affiliation><inist:fA14 i1="03"><s1>Norweigen Centre for Movement Disorders, Stavenger University Hospital</s1>
<s2>Stavenger</s2>
<s3>NOR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Institute of Clinical Medicine, University of Bergen</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Leverenz, J B" sort="Leverenz, J B" uniqKey="Leverenz J" first="J. B." last="Leverenz">J. B. Leverenz</name>
<affiliation><inist:fA14 i1="05"><s1>Mental Illness and Parkinson's Disease Research Education and Clinical Centers, VA-PSHCS, and Departments of Neurology and Psychiatry and Behavioral Sciences, University of Washington</s1>
<s2>Seattle, WA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Barone, P" sort="Barone, P" uniqKey="Barone P" first="P." last="Barone">P. Barone</name>
<affiliation><inist:fA14 i1="06"><s1>Dipartimento di Scienze Neurologiche, Università Federico II di Napoli</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weintraub, D" sort="Weintraub, D" uniqKey="Weintraub D" first="D." last="Weintraub">D. Weintraub</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Pennsylvania</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E." last="Tolosa">E. Tolosa</name>
<affiliation><inist:fA14 i1="08"><s1>Parkinson's Disease and Movement Disorders Unit, Institut Clinic de Neurociencies, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic de Barcelona, Institut d'lnvestigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name>
<affiliation><inist:fA14 i1="09"><s1>INSERM.UPMC UMRS 610, Federation of Neurology, Salpêtrière Hospital; University of Paris</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0445025</idno>
<date when="2008">2008</date>
<idno type="stanalyst">PASCAL 08-0445025 INIST</idno>
<idno type="RBID">Pascal:08-0445025</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000626</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Diagnosis and management of Parkinson's disease dementia</title>
<author><name sortKey="Poewe, W" sort="Poewe, W" uniqKey="Poewe W" first="W." last="Poewe">W. Poewe</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gauthier, S" sort="Gauthier, S" uniqKey="Gauthier S" first="S." last="Gauthier">S. Gauthier</name>
<affiliation><inist:fA14 i1="02"><s1>Alzheimer's Disease Research Unit, McGill Centre for Studies in Aging, Douglas Mental Health University Institute</s1>
<s2>Montréal, QC</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Aarsland, D" sort="Aarsland, D" uniqKey="Aarsland D" first="D." last="Aarsland">D. Aarsland</name>
<affiliation><inist:fA14 i1="03"><s1>Norweigen Centre for Movement Disorders, Stavenger University Hospital</s1>
<s2>Stavenger</s2>
<s3>NOR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="04"><s1>Institute of Clinical Medicine, University of Bergen</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Leverenz, J B" sort="Leverenz, J B" uniqKey="Leverenz J" first="J. B." last="Leverenz">J. B. Leverenz</name>
<affiliation><inist:fA14 i1="05"><s1>Mental Illness and Parkinson's Disease Research Education and Clinical Centers, VA-PSHCS, and Departments of Neurology and Psychiatry and Behavioral Sciences, University of Washington</s1>
<s2>Seattle, WA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Barone, P" sort="Barone, P" uniqKey="Barone P" first="P." last="Barone">P. Barone</name>
<affiliation><inist:fA14 i1="06"><s1>Dipartimento di Scienze Neurologiche, Università Federico II di Napoli</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Weintraub, D" sort="Weintraub, D" uniqKey="Weintraub D" first="D." last="Weintraub">D. Weintraub</name>
<affiliation><inist:fA14 i1="07"><s1>Department of Psychiatry, University of Pennsylvania</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tolosa, E" sort="Tolosa, E" uniqKey="Tolosa E" first="E." last="Tolosa">E. Tolosa</name>
<affiliation><inist:fA14 i1="08"><s1>Parkinson's Disease and Movement Disorders Unit, Institut Clinic de Neurociencies, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic de Barcelona, Institut d'lnvestigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Dubois, B" sort="Dubois, B" uniqKey="Dubois B" first="B." last="Dubois">B. Dubois</name>
<affiliation><inist:fA14 i1="09"><s1>INSERM.UPMC UMRS 610, Federation of Neurology, Salpêtrière Hospital; University of Paris</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">International journal of clinical practice : (Esher)</title>
<title level="j" type="abbreviated">Int. j. clin. pract. : (Esher)</title>
<idno type="ISSN">1368-5031</idno>
<imprint><date when="2008">2008</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">International journal of clinical practice : (Esher)</title>
<title level="j" type="abbreviated">Int. j. clin. pract. : (Esher)</title>
<idno type="ISSN">1368-5031</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Clinical management</term>
<term>Dementia</term>
<term>Diagnosis</term>
<term>Medicine</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Diagnostic</term>
<term>Conduite à tenir</term>
<term>Démence</term>
<term>Médecine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Parkinson's disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer's disease (AD). Cholinergic deficits, a feature of both AD and PDD, underlie the rationale for cholinesterase inhibitor therapy in both conditions. In clinical practice, it is important that PDD should be recognised and appropriately treated. This review aims to outline the recently proposed clinical diagnostic criteria for PDD and to summarise the guidelines/recommendations published since 2006 on the use of cholinesterase inhibitors in the management of PDD. Although the cholinesterase inhibitor rivastigmine has recently been approved for the management of PDD, there remains a need for the development of novel therapies that can affect key mechanisms of the disease or prevent/delay patients with PD and mild cognitive impairment from progressing to PDD.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1368-5031</s0>
</fA01>
<fA03 i2="1"><s0>Int. j. clin. pract. : (Esher)</s0>
</fA03>
<fA05><s2>62</s2>
</fA05>
<fA06><s2>10</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Diagnosis and management of Parkinson's disease dementia</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>POEWE (W.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GAUTHIER (S.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>AARSLAND (D.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LEVERENZ (J. B.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>BARONE (P.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>WEINTRAUB (D.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>TOLOSA (E.)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>DUBOIS (B.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Alzheimer's Disease Research Unit, McGill Centre for Studies in Aging, Douglas Mental Health University Institute</s1>
<s2>Montréal, QC</s2>
<s3>CAN</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Norweigen Centre for Movement Disorders, Stavenger University Hospital</s1>
<s2>Stavenger</s2>
<s3>NOR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Institute of Clinical Medicine, University of Bergen</s1>
<s2>Bergen</s2>
<s3>NOR</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Mental Illness and Parkinson's Disease Research Education and Clinical Centers, VA-PSHCS, and Departments of Neurology and Psychiatry and Behavioral Sciences, University of Washington</s1>
<s2>Seattle, WA</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Dipartimento di Scienze Neurologiche, Università Federico II di Napoli</s1>
<s2>Naples</s2>
<s3>ITA</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Psychiatry, University of Pennsylvania</s1>
<s2>Philadelphia, PA</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Parkinson's Disease and Movement Disorders Unit, Institut Clinic de Neurociencies, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic de Barcelona, Institut d'lnvestigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona</s1>
<s2>Barcelona</s2>
<s3>ESP</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>INSERM.UPMC UMRS 610, Federation of Neurology, Salpêtrière Hospital; University of Paris</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA20><s1>1581-1587</s1>
</fA20>
<fA21><s1>2008</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>15561</s2>
<s5>354000185233900160</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2008 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>47 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>08-0445025</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>International journal of clinical practice : (Esher)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Parkinson's disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer's disease (AD). Cholinergic deficits, a feature of both AD and PDD, underlie the rationale for cholinesterase inhibitor therapy in both conditions. In clinical practice, it is important that PDD should be recognised and appropriately treated. This review aims to outline the recently proposed clinical diagnostic criteria for PDD and to summarise the guidelines/recommendations published since 2006 on the use of cholinesterase inhibitors in the management of PDD. Although the cholinesterase inhibitor rivastigmine has recently been approved for the management of PDD, there remains a need for the development of novel therapies that can affect key mechanisms of the disease or prevent/delay patients with PD and mild cognitive impairment from progressing to PDD.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B01</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Diagnostic</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Diagnosis</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Diagnóstico</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Conduite à tenir</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Clinical management</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Actitud médica</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Démence</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Dementia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Demencia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Médecine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Medicine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Medicina</s0>
<s5>05</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>41</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>41</s5>
</fC07>
<fN21><s1>287</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 08-0445025 INIST</NO>
<ET>Diagnosis and management of Parkinson's disease dementia</ET>
<AU>POEWE (W.); GAUTHIER (S.); AARSLAND (D.); LEVERENZ (J. B.); BARONE (P.); WEINTRAUB (D.); TOLOSA (E.); DUBOIS (B.)</AU>
<AF>Department of Neurology, Medical University Innsbruck/Innsbruck/Autriche (1 aut.); Alzheimer's Disease Research Unit, McGill Centre for Studies in Aging, Douglas Mental Health University Institute/Montréal, QC/Canada (2 aut.); Norweigen Centre for Movement Disorders, Stavenger University Hospital/Stavenger/Norvège (3 aut.); Institute of Clinical Medicine, University of Bergen/Bergen/Norvège (3 aut.); Mental Illness and Parkinson's Disease Research Education and Clinical Centers, VA-PSHCS, and Departments of Neurology and Psychiatry and Behavioral Sciences, University of Washington/Seattle, WA/Etats-Unis (4 aut.); Dipartimento di Scienze Neurologiche, Università Federico II di Napoli/Naples/Italie (5 aut.); Department of Psychiatry, University of Pennsylvania/Philadelphia, PA/Etats-Unis (6 aut.); Parkinson's Disease and Movement Disorders Unit, Institut Clinic de Neurociencies, and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Hospital Clinic de Barcelona, Institut d'lnvestigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona/Barcelona/Espagne (7 aut.); INSERM.UPMC UMRS 610, Federation of Neurology, Salpêtrière Hospital; University of Paris/Paris/France (8 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>International journal of clinical practice : (Esher); ISSN 1368-5031; Royaume-Uni; Da. 2008; Vol. 62; No. 10; Pp. 1581-1587; Bibl. 47 ref.</SO>
<LA>Anglais</LA>
<EA>Parkinson's disease (PD) has long been considered predominantly a motor disorder. However, its frequent association with dementia, which contributes significantly to the morbidity and mortality of the condition, is gaining increasing recognition. PD dementia (PDD) has a unique clinical profile and neuropathology, distinct from Alzheimer's disease (AD). Cholinergic deficits, a feature of both AD and PDD, underlie the rationale for cholinesterase inhibitor therapy in both conditions. In clinical practice, it is important that PDD should be recognised and appropriately treated. This review aims to outline the recently proposed clinical diagnostic criteria for PDD and to summarise the guidelines/recommendations published since 2006 on the use of cholinesterase inhibitors in the management of PDD. Although the cholinesterase inhibitor rivastigmine has recently been approved for the management of PDD, there remains a need for the development of novel therapies that can affect key mechanisms of the disease or prevent/delay patients with PD and mild cognitive impairment from progressing to PDD.</EA>
<CC>002B01; 002B17G</CC>
<FD>Maladie de Parkinson; Diagnostic; Conduite à tenir; Démence; Médecine</FD>
<FG>Pathologie de l'encéphale; Syndrome extrapyramidal; Maladie dégénérative; Pathologie du   système nerveux central; Pathologie du   système nerveux</FG>
<ED>Parkinson disease; Diagnosis; Clinical management; Dementia; Medicine</ED>
<EG>Cerebral disorder; Extrapyramidal syndrome; Degenerative disease; Central nervous system disease; Nervous system diseases</EG>
<SD>Parkinson enfermedad; Diagnóstico; Actitud médica; Demencia; Medicina</SD>
<LO>INIST-15561.354000185233900160</LO>
<ID>08-0445025</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000626 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000626 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:08-0445025
   |texte=   Diagnosis and management of Parkinson's disease dementia
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Diagnosis and management of Parkinson's disease dementia

Diagnosis and management of Parkinson's disease dementia

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri